Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nammi Therapeutics Inc
Zumutor Biologics Inc.
National Cancer Institute (NCI)
SystImmune Inc.
Merck Sharp & Dohme LLC
Myeloid Therapeutics
Avacta Life Sciences Ltd
Innate Pharma
Dren Bio
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Exelixis
Jonsson Comprehensive Cancer Center
Xencor, Inc.
University of Virginia
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Orion Biotechnology Polska Sp. z o.o.
Daiichi Sankyo
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Xencor, Inc.
Pliant Therapeutics, Inc.
Atreca, Inc.
Fate Therapeutics
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Xencor, Inc.
Ludwig Institute for Cancer Research
PACT Pharma, Inc.
Gossamer Bio Inc.
EMD Serono
Incyte Corporation
Incyte Corporation
Merrimack Pharmaceuticals
Corcept Therapeutics